Table 2.
Pharmacokinetic Parameters of α-FLT3-scFv and α-FLT3-A192 nanoparticles following IV administration using a non-compartmental analysis
| Parameter (Unit) | α-FLT3 scFva (n=5) | α-FLT3-A192a (n=5) | p value |
|---|---|---|---|
| CL/g BW (ml/h·g) | 0.03 (0.01) | 0.07 (0.02) | 0.009 |
| AUC (yM*h) | 7.14 (2.14) | 39.7 (14.9) | 0.001 |
| AUMC (μM*h2) | 11.7 (1.70) | 665 (238) | 0.0003 |
| MRT (h) | 1.74 (0.46) | 18.7 (7.8) | 0.001 |
| Vd/g BW (ml/g) | 0.03 (0.01) | 0.17 (0.09) | 0.008 |
| Vss/g (ml/g) | 0.06 (0.04) | 1.50 (0.76) | 0.003 |
a
values indicate the mean (standard deviation) of n=5 following a dose of 2.7 nanomoles of rhodamine-labeled α-FLT3-A192 (1.7 nanomoles of the total dose of α-FLT3-A192) per gram of mouse body weight or a dose of 0.2 nanomoles of rhodamine-labeled α-FLT3 scFv (0.8 nanomoles of the total dose of α-FLT3 scFv) alone.